125 related articles for article (PubMed ID: 38895618)
1. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
Yang Y; Liu Y; Mao Z; Mao J; Jin Y
Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
[TBL] [Abstract][Full Text] [Related]
2. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
3. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
[No Abstract] [Full Text] [Related]
4. Improving access to medicines and beyond: the national volume-based procurement policy in China.
Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
[TBL] [Abstract][Full Text] [Related]
5. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
Sun Z; Na X; Chu S
Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
[TBL] [Abstract][Full Text] [Related]
6. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
7. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
[No Abstract] [Full Text] [Related]
8. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
[TBL] [Abstract][Full Text] [Related]
9. Patients' attitudes towards switching to national volume-based procurement (NVBP) Drugs-a qualitative investigation in Wuhan, China.
Tao J; Li S; Xu Q; Gong S; Zeng F
BMC Health Serv Res; 2023 Jan; 23(1):62. PubMed ID: 36670463
[TBL] [Abstract][Full Text] [Related]
10. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
[No Abstract] [Full Text] [Related]
11. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
[TBL] [Abstract][Full Text] [Related]
12. Does China improve social welfare after implementing the national volume-based procurement?
Wang H; Huo YT; Zhuang Q
Front Pharmacol; 2023; 14():1178026. PubMed ID: 37886133
[No Abstract] [Full Text] [Related]
13. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China.
Yuan J; Lu ZK; Xiong X; Jiang B
BMJ Glob Health; 2021 Sep; 6(9):. PubMed ID: 34518200
[TBL] [Abstract][Full Text] [Related]
14. Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design.
Hua YF; Lu J; Bai B; Zhao HQ
Front Public Health; 2021; 9():809453. PubMed ID: 35178375
[TBL] [Abstract][Full Text] [Related]
15. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
Coghlan R; Stephens P; Mwale B; Siyanga M
Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
[TBL] [Abstract][Full Text] [Related]
16. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
17. The Brazilian private pharmaceutical market after the first ten years of the generics law.
Bertoldi AD; Wagner AK; Emmerick ICM; Chaves LA; Stephens P; Ross-Degnan D
J Pharm Policy Pract; 2019; 12():18. PubMed ID: 31417682
[TBL] [Abstract][Full Text] [Related]
18. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
Gu Y; Zhuang Q
Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
[No Abstract] [Full Text] [Related]
19. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
20. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
